Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2025
Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Nov 5, 2024
Product Development
Arcus data the latest twist in the TIGIT story
BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
BioCentury | Oct 31, 2024
Deals
Trend watch: Degrader deals show glues are sticking
At least seven molecular glue degrader deals announced this year; less deal activity for classical PROTACs
BioCentury | Oct 29, 2024
Deals
Novartis adds another degrader, this time from Monte Rosa
Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Oct 21, 2024
Product Development
EGFR: A best-in-class strategy study
The target is one of industry’s most notable case studies in continued product differentiation and market growth
BioCentury | Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
BioCentury | Aug 15, 2024
Finance
Venture Report: Halda bringing RIPTACs into clinic with crossover round
Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis
BioCentury | Jul 23, 2024
Product Development
Clinical Report: Ionis’ therapy for Angelman syndrome heading for Phase III
Plus: Data from Innovent, Agenus, Merck, Bayer and Orion
BioCentury | May 24, 2024
Product Development
J&J data at ASCO probe new target space, toxicity limits for actinium
The radiotherapy is one of multiple modalities J&J is testing against KLK2, which could enable tumor-specific targeting across prostate cancer stages
BioCentury | Apr 16, 2024
Deals
Deals report: Vertex’s biggest deal yet, and more
Novartis gets two androgen receptor protein degraders from Arvinas and Genentech-Adaptimmune terminate allogeneic T cell therapy deal
Items per page:
1 - 10 of 690